🔎 Trials Near Me

Home › Precursor T-Cell Lymphoblastic Leukemia-Lymphoma › Ohio

Pag-aaral pangklinika para sa Precursor T-Cell Lymphoblastic Leukemia-Lymphoma sa Ohio

6 pag-aaral para sa Precursor T-Cell Lymphoblastic Leukemia-Lymphoma ang naghahanap ng mga kalahok sa mga site sa Ohio.

Mga Lungsod sa Ohio

Opisyal na teksto ng pag-aaral (English)

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

  • Ohio State University Comprehensive Cancer Center, Columbus
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT04301076

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

  • Ohio State University Comprehensive Cancer Center, Columbus
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 27, 2026 · NCT07356245

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

  • Oncology Hematology Care, Cincinnati
  • Cincinnati Children's Hospital Medical Center, Cincinnati
Nagre-recruitPhase 2
6 Months · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06514794

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

  • Nationwide Children's Hosptial, Columbus
Nagre-recruitPhase 1
Hanggang edad 39 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT04972942

A Registry for People With T-cell Lymphoma

  • Ohio State University (Data Collection Only), Columbus
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update May 20, 2026 · NCT05978141

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

  • Ohio State University Comprehensive Cancer Center, Columbus
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 10, 2026 · NCT04848064

Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.